Canaccord raised the firm’s price target on iRhythm (IRTC) to $193 from $170 and keeps a Buy rating on the shares. The firm updated its estimates to update to better reflect volume andpricing trends in the business.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- CoreWeave upgraded, Lululemon downgraded: Wall Street’s top analyst calls
- iRhythm initiated with an In Line at Evercore ISI
- Irhythm Technologies: Strategic Market Expansion and Clinical Efficacy Drive Buy Rating
- iRhythm Technologies: Strategic Partnerships and Growth Potential Drive Buy Rating
- Positive Buy Rating for Irhythm Technologies Supported by AMALFI Trial Success